As many readers know, I personally became a patient at the end of 2017 when I underwent a cellular orthopedic procedure to my knees. In January of 2018, I underwent a similar intervention for my hips. Included in my decision making was the desire to maintain an unlimited professional commitment, a full recreational athletic schedule, and continue to have the capacity to expand my clinical, research and educational integration. One week ago, I hosted two leading orthopedic surgeons from St. Petersburg, Russia for a full day of Cellular Orthopedic instruction. On Tuesday, I continued the initiative while performing a Bone Marrow Concentrate /Stem cell intervention into the arthritic right hip of one of my visitors. On Saturday, I participated in a full day workshop focused on subchondroplasty; an area where I have gained recognition because of my Prospective Clinical Study on the particular treatment alternative when indicated.
This past Sunday and Monday, I met with a project director of a start-up regenerative medicine company seeking to have me design and carry out a clinical trial for a next-generation Amniotic Fluid derivative. There are no published outcomes studies at this time to support the use of Amniotic Fluid offerings advertised in the newspaper. The claims regarding viable stem cells following collection, sterilization, processing, freezing and fast thawing have not withstood scientific scrutiny nor has any benefit been statistically proven. The new company behind the contemporary manufacturing process does not want to show and tell; but rather, scientifically document efficacy and that is why I am interested.
I guess the message behind this blog is that I have experienced a fabulous result in my arthritic knees and hips allowing me to enjoy a relatively symptom-free, fully active lifestyle, based on a Cellular Orthopedic option, scientifically and clinically proven to succeed. The next question is then why isn’t cellular orthopedics affective on all? While there have been several publications regarding a genetic basis for success or failure of biologic interventions, there have been few actual studies to measure Molecular Biomarkers of Knee Pathology. To that end, I am determining the fiscal reality, of recovering a patient’s synovial fluid prior to treatment and measuring those biologic markers. Lots going on, for sure; however, remember that everything I do is based on science, my previous career as an orthopedic surgeon pioneering joint replacements, and my present and ongoing efforts at evidence-based Cellular Orthopedics.
To see how I might help you postpone or avoid a total joint replacement while returning to a pain-free active lifestyle call (847) 390-7666 to schedule an appointment or view my website at WWW.SheinkopMD.com.
Hip osteoarthritis (OA) exerts a significant burden on society, affecting 3% of Americans aged >30 years. Recent advances in the understanding of the pathoanatomy and pathomechanics of the hip have led to treatment options for young adults with hip pain. Femoroacetabular impingement, specifically cam-type femoroacetabular impingement, hip dysplasia, and the sequelae of pediatric hip disease can predispose the hip to early OA. However, many patients with abnormal anatomic findings do not develop early OA, suggesting that there exist other patient characteristics that are protective despite abnormal bony anatomy. Outcome studies show that arthroscopic and open hip procedures improve pain and function in patients with symptomatic hips. However, there is currently limited evidence that these procedures extend the life of the patient’s natural hip. Additional studies are needed to determine protective or adaptive factors in patients with abnormal anatomy who do not develop early OA and to determine whether joint preserving hip surgery extends the life of the native hip joint.
Review Article:Natural History of Structural Hip Abnormalities and the Potential for Hip Preservation
James D. Wylie, Christopher L. Peters, Stephen Kenji Aoki
What makes the article so interesting to me is first, I played a role in training one of the authors in my earlier academic career. More important is the role I am now playing in helping to preserve the life of the hip joint with a needle instead of a knife and extending the life of the “native hip joint”. The latter is done via Cellular Orthopedics. By introducing Stem Cells, Platelets, Precursor Cells, and Growth Factors, I am now able to address arthritis at a Bio-Immune level, possibly regenerate cartilage, potentially influence healing of the torn acetabular labrum, certainly reverse the secondary inflammation and thereby diminish pain and improve function in the abnormal hip joint.
It takes an evaluation in my office including the history, a physical examination and my review of your hip images after which I am able to customize the Cellular Orthopedic intervention that will help with joint preservation and potentially, joint regeneration. Our Outcomes studies continue and it is the result of ongoing data collection that allows me to extend the life of your native hip. Call (312) 475 1893 to schedule a consultation. You may visit my web site at www.sheinkopmd.com
Tags: cellular orthopedics, Dysplasia, Hip osteoarthritis, Hip pain, hip surgery, platelets, stem cells, torn labrum
Over five years ago, I exchanged a scalpel for a needle and thus entered a developing discipline of cellular orthopedics. My goal was to assist patients with joint afflictions and orthopedic conditions delay, perhaps avoid a surgical procedure by capturing their body’s restorative or regenerative potential and applying evidence-based techniques.
To meet these goals, I introduced the same integration of clinical care with patient outcomes that I had pioneered over a 37-year Joint Replacement career at a major academic orthopedic center in Chicago where I retired as director of the Joint replacement Program. A data base was established and the outcomes of every patient who has undergone a Cellular Orthopedic procedure has been entered into that Data Base regulated by IRB over-site.
Now I am ready to begin sharing the outcomes we have gathered with statistically documented evidence concerning who is a candidate for Cellular Orthopedics, what is the best customized approach for a particular regenerative or restorative procedure and when to advise a patient that surgery might be a better option.
This past weekend, I had a poster exhibit on display at the TOBI meeting in Las Vegas in which I reported preliminary outcomes of a combined Intraarticular and Intraosseous (subchondroplasty) Bone Marrow Concentrate intervention for grades 2 and 3 Osteoarthritis at the knee. I am now working on four presentations as an invited guest speaker at the October meeting of Med Rebels, a well-attended regenerative medicine conference for continuing education credits concerning patient outcomes for different aspects of Cellular Orthopedic recorded in my data base.
What we have learned in these past five years plus is that everyone doesn’t respond to regenerative medicine interventions. You may best gain in-site as to why by reading a blog that I wrote exploring reasons for lack of successes: When Bone Marrow Concentrate Intervention Fails. On the other hand, in part due to the evidence I have gained as well as continuing technological advances, I have a better idea as to who is a candidate for regenerative medicine.
To learn if you are a candidate, schedule a consultation at (847) 390-7666. You may access my web site where you will find my webinar www.Ilcellulartherapy.com.
Tags: arthritis, artificial joint, blood plasma, bone marrow, bone marrow lesion, cellular orthopedics, joint pain, joint replacement, knee pain, Med Rebels, Orthopedic Surgeon, Orthopedics, Osteoarthritis, platelet, stem cells, surgery, TOBI
On Wednesday, I completed several bone marrow concentrate procedures for patients with arthritic knees. You will recall that Concentrated Bone Marrow contains living Adult Mesenchymal Stem Cells, Growth Factors, Platelets, Exosomes, Precursor Cells and more allowing for pain relief, improved function and possible regeneration in those afflicted by arthritis. In the afternoon, four patients underwent Autologous Platelet and Growth Factor interventions; two in the hip and two in their knees. An example of the outcome, now four months following intervention in my own knees and hips, I spent last weekend hiking along several spring creeks, fly fishing in Southwest Wisconsin in the morning and planting over 150 Lilly bulbs in the afternoon. Admittedly, I slept well on Saturday and Sunday night but visited the health club on these past Tuesday and Wednesday evenings for my fitness routines.
On Monday, we finalized and edited a manuscript reporting the results of 56 patients with arthritic knees, followed for 2 to 4 years having received Bone Marrow Concentrate. Using the same outcome metrics and statistical tabulation methods I had employed as a joint replacement surgeon, this study is one of the most significant trials ever completed and to be published in Cellular Orthopedics. Our study not only will help determine the indications for a “stem cell” procedure, but also assist in determining how long the benefits will last, and provide a road map for when adjunct or repeat interventions are indicated. Now the physician will be better prepared to help a patient decide between a Total Joint Replacement and a Cellular Orthopedic intervention on an evidence based knowledge.
I am writing this Blog while flying to San Jose, California where I am partaking in advanced training that will allow me to expand my regenerative medicine practice to the low back. Again and again, patients ask as to what I might offer to address low back pain and disc disease now that I have successfully intervened in an arthritic hip or knee. Indications and techniques for addressing the lumbar spine will make up the curriculum enabling me to add discogenic and degenerative arthritic conditions of the low back to my scope of regenerative care by mid May.
To the patient who called, “I heard through the grapevine that it doesn’t work”, you may avoid falling victim to the Fake Stem Cell claims in newspaper ads or via celebrity testimonials; those in amniotic fluid are dead on arrival to you. Seek scientific evidence at (847) 390-7666 or learn more on my web site where you may watch my webinar www.Ilcellulartherapy.com.
Tags: Adult Mesenchymal Stem Cells, arthritic conditions, back pain, cellular orthopedics, Concentrated Bone Marrow, degenerative disc disease, discogenic, Exosomes, Growth Factors, Hip pain, joint pain, knee pain, Osteoarthritis, platelets, Precursor Cells, Regenerative Pain Center, shoulder pain, stem cell therapy
I am sitting at my computer this morning writing the weekly Blog posting and not attending the IOF meeting taking place today in Broomfield, Colorado; yet I am reporting about the meeting. Instead of attending, I am preparing for a week-long ski adventure with my family next week in Vail, Colorado while trying to catch up in my practice. How is it than possible that I know what is taking place at the meeting? Listed below are five of the 10 ongoing or completed cellular orthopedic clinical trials in which I am a principal investigator or co-researcher. The preliminary and final data resulting from these clinical research initiatives is the outcomes foundation for what is being presented at the IOF podium today and tomorrow.
1) Stem Cell Counts and the Outcome of Bone Marrow Concentrate intra-articular and intra-osseous (subchondroplasty) interventions at the knee for grades 2 and 3 OA. (supported in part by Celling). Ongoing
2) Outcomes of Bone Marrow Concentrate (stem cell, platelet and growth factor) Intervention at the Knee for Grades 2 and 3 OA in 50 patients at 2 to 4 years. (supported in part by Regenexx)
3) Outcomes of Intra-articular Bone Marrow Concentrate versus those of combined Intraarticular and Intraosseous interventions for grades 2 and 3 OA at the knee at one year. (self-funded). Ongoing
4) How does the PRP and Mononucleated cell count affect the outcome of a BMC intervention for grades 2 and 3 Knee OA? (a joint project with Greyledge) Ongoing
5) Safety and Efficacy of Percutaneous Injection of Micro-Fractured Adipose Tissue for grade 4 Osteoarthritic Knees, minimum follow-up of 18 months in 30 patients (supported in part by Lipogems)
I had to prioritize; and since most of the arthritis data being presented is all or in part mine, I already know the subject matter. By staying home, I also found the opportunity to browse “stem cell” websites as suggested by ads in today’s newspapers or introduced by email blasts this week. Wow, a patient acting more like a consumer is really at risk for succumbing to Regenerative Medicine “false news”.
If you want to learn more about the difference between the stem cell purveyors and a legitimate, FDA compliant, evidence based, cellular orthopedics initiative, call to schedule a consultation or to get a second opinion.
You may schedule a visit at (847) 390-7666
You may access my website and watch a webinar at www.ilcellulartherapy.com
Tags: arthritis, bone marrow, Celling, cellular orthopedics, Growth Factors, Hip pain, International Orthopedics Foundation, joint pain, knee arthritis, knee intervention, knee pain, lipogems, Micro-Fractured Adipose, Osteoarthritis, PRP, regenerative medicine, Regenexx, stem cells, Subchondroplasty
The March 2018, edition of Consumer Reports includes an article written by Jenseen Interlandi that is worth the read for both what it does say and the questions it raises. I welcome the critical review of Stem Cell Therapy whenever an article appears because I too am critical of the charlatans, camp followers and those fleecing the public. In the Interlandi article, the reader immediately finds one such example of a so-called Institute in Tampa, Florida victimizing those with chronic pulmonary diseases; but you don’t have to travel to Florida to find such practices as were reported on by Fox 32’s Sylvia Perez in her investigation featured Monday, January 29. If you missed it, all you need to do is click on the hi lighted below:
Equally egregious are the in your face, regularly appearing ads in our newspapers for stem cell treatment via amniotic fluid. If there were viable stem cells in amniotic fluid, the non-autologous (yours to you) nature of said treatment is contrary to FDA compliance. On the other hand, repeated microscopic studies confirm that no viable stem cells are to be found in amniotic fluid once recovered by amniocentesis, sterilization, processing, freezing and eventually fast thawing for injection.
I will attempt to respond to the “Climate of Confusion” critique found as a headline inside the article. Rather than repeat the lengthy text, I assume I have piqued your curiosity and you will buy the periodical and read. While it is true that I use patient testimonials to promote my interventions, what I do in my practice is indeed based on an increasing data base of clinical outcomes. We practice evidence based cellular orthopedics as a result of the largest and longest running outcomes documentation data base in regenerative medicine. On February 15, at the Interventional Orthopedics Foundation annual meeting taking place outside of Boulder, Colorado, my colleague David Karli will report on my outcomes at one year using a combined intra-articular (into the joint) and intra-osseous (into the bone adjacent to the joint) at one year and comparing the outcomes to those documented at one year following intra-articular injection alone. Patients who received the combined intervention reported an 89% average diminution of pain at one year as compared to a 40% decrease in those who underwent intra-articular Bone Marrow Concentrate intervention alone. This is one example of what may be gleaned from a data base.
In conclusion, the obvious question becomes, “How to Protect Yourself” from unscrupulous stem cell therapy? My response, call and schedule an appointment or view my website and webinar:
I will answer your questions, avoid hype and review the fine print with you.